Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer

Background: Targeting the epidermal growth factor receptor and angiogenesis have proven useful strategies against metastatic colorectal cancer. The benefit of combining inhibitors of both pathways is unknown. Patients and methods: Patients with previously untreated metastatic colorectal cancer were...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2007-07, Vol.18 (7), p.1185-1189
Hauptverfasser:	Meyerhardt, JA, Stuart, K, Fuchs, CS, Zhu, AX, Earle, CC, Bhargava, P, Blaszkowsky, L, Enzinger, P, Mayer, RJ, Battu, S, Lawrence, C, Ryan, DP
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents bevacizumab Biological and medical sciences colorectal cancer erlotinib FOLFOX Gastroenterology. Liver. Pancreas. Abdomen Medical sciences Pharmacology. Drug treatments Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!